Chronic Heart Failure Market to Observe Stunning Growth at a CAGR of 10% by 2034 Owing to Strong Uptake of Entresto and approved SGLT2 Inhibitors along with Emergence of New Class of Therapies | DelveInsight

Several leading classes of therapies are exploring diverse mechanisms of action to treat CHF, including SGLT2 inhibitors, cardiac myosin activators, myeloperoxidase inhibitors, mineralocorticoid receptor antagonists, GLP-1 receptor agonists, cell therapies, and more. This growing focus is expected to drive the chronic heart failure market forward. In summary, the existing blockbuster therapies such as Entresto, recently approved SGLT2 inhibitors, and Soluble guanylate cyclase (sGC) stimulators, along with emerging cell therapies, peptides, monoclonal antibodies, and small molecules, together have the potential to drive the existing market along with securing a significant market share upon introduction of new entrants to the CHF treatment landscape.

LAS VEGAS, Jan. 22, 2025 /PRNewswire/ -- DelveInsight's Chronic Heart Failure Market Insights report includes a comprehensive understanding of current treatment practices, chronic heart failure emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan].

https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg

Key Takeaways from the Chronic Heart Failure Market Report

    --  According to DelveInsight's analysis, the market size for chronic heart
        failure was found to be approximately USD 5.5 billion in the US in 2023.
    --  Among the 7MM, the US contributed the largest market share of the total
        CHF market size and will continue to experience a steep rise in the
        market size throughout the forecast period.
    --  As per DelveInsight's estimate, the total diagnosed prevalent cases of
        CHF in the 7MM were approximately  20 million in 2023. Heart failure
        with preserved ejection fraction (HFpEF) contributed to most of the
        cases.
    --  Within class-specific diagnosed prevalence of Heart failure, NYHA class
        II and class III contribute the maximum.
    --  Established chronic heart failure companies with approved therapies in
        the market are Novartis, Otsuka, Boehringer Ingelheim/Eli Lilly,
        Bayer/Merck, Amgen/Servier, scPharmaceuticals, and Lexicon
        Pharmaceuticals/Viatris. In addition, Daiichi Sankyo and American Regent
        are targeting adult patients with heart failure who are iron deficient.
    --  Among all the approved therapies, Novartis and Otsuka's Entresto,
        approved since 2015 in the US, is still the leading therapy generating
        more than USD 4 billion in the 7MM in 2023. Among, Eli Lilly's Jardiance
        and AstraZeneca's Farxiga, both SGLT2 inhibitors,  Farxiga is the
        leading prescribed SGLT2 inhibitor globally by volume
    --  Leading chronic heart failure companies developing emerging therapies,
        such as Cytokinetics, Bayer, Eli Lilly, BioCardia, Mesoblast, Tenax
        Therapeutics, Novo Nordisk, AstraZeneca, Boehringer Ingelheim, Bristol
        Myers Squibb, Intra-Cellular Therapies, Cardurion Pharmaceuticals, Rivus
        Pharmaceuticals, and others are developing novel chronic heart failure
        drugs that can be available in the chronic heart failure market in the
        coming years. The promising chronic heart failure therapies in the
        pipeline include Omecamtiv Mecarbil, KERENDIA (finerenone), Tirzepatide
        (LY3298176), CardiAMP Cell Therapy, Ziltivekimab (NN6018), REVASCOR
        (rexlemestrocel-L), Levosimendan (TNX-103), Semaglutide, Balcinrenone
        (AZD9977) + dapagliflozin, Mitiperstat (AZD4831), Vicadrostat (BI
        690517) + Empagliflozin, Cimlanod (CXL-1427/BMS-986231), Lenrispodun
        (ITI - 214), CRD-740, HU6, and others.
    --  In October 2024, Viatris entered into an exclusive licensing agreement
        with Lexicon Pharmaceuticals for INPEFA (sotagliflozin) in all markets
        outside of the US and EU.
    --  In September 2024, Bayer presented the late-breaking data of Phase III
        FINE-HEART findings of KERENDIA (finerenone) during a Hot Line session
        at the European Society of Cardiology (ESC) Congress 2024.
    --  In May 2024, Eli Lilly and Company committed an additional USD 5.3
        billion manufacturing investment in the company's newest Indiana site to
        boost API production for tirzepatide and pipeline medicines.
    --  AstraZeneca expects the data of the Phase III BalanceD-HF trial of
        balcinrenone (AZD9977) + dapagliflozin for heart failure in 2025.

Discover which therapies are expected to grab the major chronic heart failure market share @ Chronic Heart Failure Market Report

Chronic Heart Failure Overview

Chronic heart failure is a long-term condition in which the heart's ability to pump blood efficiently is reduced, leading to inadequate circulation of oxygen and nutrients to meet the body's needs. The primary causes of CHF include coronary artery disease, high blood pressure, diabetes, cardiomyopathy, valvular heart disease, and previous heart attacks. Lifestyle factors like obesity, smoking, excessive alcohol consumption, and a sedentary lifestyle can also contribute to its development.

The symptoms of CHF vary in severity and may include persistent fatigue, shortness of breath, swelling in the legs, ankles, or abdomen, rapid or irregular heartbeat, and difficulty exercising. Advanced cases can lead to severe fluid retention, wheezing, and an inability to carry out daily activities.

Diagnosis typically involves a comprehensive medical history review and a physical examination, followed by tests like an ECG to assess heart rhythm, echocardiography to evaluate heart structure and function, blood tests, chest X-rays, and stress tests. Early diagnosis and management are crucial to improving quality of life and preventing complications.

Chronic Heart Failure Epidemiology Segmentation

The chronic heart failure epidemiology section provides insights into the historical and current chronic heart failure patient pool and forecasted trends for the 7MM. It helps recognize the causes of current and forecasted patient trends by exploring numerous studies and views of key opinion leaders.

The chronic heart failure market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:

    --  Total Diagnosed Prevalent Cases of Heart Failure
    --  Gender-specific Cases of Heart Failure
    --  Ejection Fraction-specific Cases of Heart Failure
    --  New York Heart Association (NYHA) Class-specific Cases of Heart Failure
    --  Type-specific Cases of Heart Failure
    --  Age-specific Cases of Heart Failure

Chronic Heart Failure Treatment Market

Current treatments for heart failure primarily rely on angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), beta-blockers, and diuretics. Additional therapies, such as aldosterone antagonists, amiodarone, antiplatelets, anticoagulants, calcium channel blockers, and nitrates, are also utilized in managing the condition.

Most treatment regimens involve a combination of therapies, with beta-blockers being among the most commonly prescribed. Among the approved treatments, Novartis' ENTRESTO has emerged as a leading drug in the congestive heart failure market. Initially slow to gain traction, ENTRESTO has become one of Novartis' key growth drivers, with revenue expected to increase in the coming years. Following its approval for use in patients with preserved ejection fraction, ENTRESTO's market presence has grown significantly.

However, ENTRESTO faces growing competition. The entry of new drugs, including SGLT2 inhibitors (such as FARXIGA and JARDIANCE) and VERQUVO, poses a challenge to ENTRESTO's dominance. Additionally, Novartis is set to lose ENTRESTO's exclusivity in the United States in 2025, raising the risk of generic competition. The company is actively engaged in several patent lawsuits to protect its position.

SGLT2 inhibitors have also gained a foothold in the CHF market. Although FARXIGA and JARDIANCE are established drugs, they are relatively new in this therapeutic area. The outlook for SGLT2 inhibitors in heart failure is promising, but AstraZeneca and Lilly/Boehringer will have limited time to solidify their positions, as FARXIGA's US patent expires in 2025 and JARDIANCE's in 2028. The recently approved SGLT2 inhibitor sotagliflozin may face challenges in capturing market share from these established treatments.

To know more about chronic heart failure treatment guidelines, visit @ Chronic Heart Failure Management

Chronic Heart Failure Pipeline Therapies and Key Companies

    --  Omecamtiv Mecarbil: Cytokinetics
    --  KERENDIA (finerenone): Bayer
    --  Tirzepatide (LY3298176): Eli Lilly and Company
    --  CardiAMP Cell Therapy: BioCardia
    --  Ziltivekimab (NN6018): Novo Nordisk
    --  REVASCOR (rexlemestrocel-L): Mesoblast
    --  Levosimendan (TNX-103): Tenax Therapeutics
    --  Semaglutide: Novo Nordisk
    --  Balcinrenone (AZD9977) + dapagliflozin: AstraZeneca
    --  Mitiperstat (AZD4831): AstraZeneca
    --  Vicadrostat (BI 690517) + Empagliflozin: Boehringer Ingelheim
    --  Cimlanod (CXL-1427/BMS-986231): Bristol Myers Squibb
    --  Lenrispodun (ITI - 214): Intra-Cellular Therapies
    --  CRD-740: Cardurion Pharmaceuticals
    --  HU6: Rivus Pharmaceuticals

Discover more about chronic heart failure drugs in development @ Chronic Heart Failure Clinical Trials

Chronic Heart Failure Market Dynamics

The chronic heart failure market dynamics are expected to change in the coming years. An increasing prevalence of cardiovascular diseases, fueled by aging populations and lifestyle-related risk factors such as obesity, hypertension, and diabetes, has significantly raised the demand for effective CHF treatments. Advances in medical technology, including innovative drug therapies, cardiac devices, and regenerative medicine, are expanding treatment options and improving patient outcomes.

Growing awareness about heart health and early diagnosis, supported by government and non-government initiatives, is also boosting market expansion. Additionally, the rising focus on personalized medicine and the development of therapies targeting the underlying molecular mechanisms of CHF are creating lucrative opportunities. The increasing healthcare expenditure and the availability of reimbursement policies in developed and emerging economies further bolster the market's growth trajectory.

Furthermore, potential therapies are being investigated for the treatment of chronic heart failure, and it is safe to predict that the treatment space will significantly impact the chronic heart failure market during the forecast period. Moreover, the anticipated introduction of emerging therapies with improved efficacy and a further improvement in the diagnosis rate are expected to drive the growth of the chronic heart failure market in the 7MM.

However several factors may impede the growth of the chronic heart failure market. A key challenge is the underdiagnosis and delayed recognition of CHF due to overlapping symptoms with other conditions and the lack of widespread access to advanced diagnostic tools in many regions. Economic constraints, particularly in low- and middle-income countries, limit patient access to costly therapies, including advanced drugs and devices.

Additionally, adherence to treatment regimens remains low due to the complexity of management protocols and the long-term nature of care, leading to suboptimal outcomes. Regulatory hurdles and lengthy approval processes for novel therapies further impede the introduction of innovative treatments. Finally, a limited understanding among general practitioners about newer guidelines and therapies reduces the referral rates to specialists, creating gaps in patient care. Addressing these barriers requires concerted efforts in education, affordability, and healthcare infrastructure.


                 Chronic Heart Failure Market
                  Report Metrics              
     
              Details



     Study Period                            
     2020-2034



     Coverage                                
     7MM [the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan].


      Chronic Heart Failure Market CAGR


      Chronic Heart Failure Market Size
       in 2023                                
     USD 8.1 Billion (7MM)


      Key Chronic Heart Failure                 Novartis, Otsuka, AstraZeneca, Merck, Amgen/Servier, scPharmaceuticals, LexiconPharmaceuticals/Viatris.Cytokinetics,
       Companies                                 Bayer, Eli Lilly and Company, BioCardia, Mesoblast, Tenax Therapeutics, Novo Nordisk, AstraZeneca, Boehringer
                                                 Ingelheim, Bristol Myers Squibb, Intra-Cellular Therapies, Cardurion Pharmaceuticals, Rivus Pharmaceuticals, and
                                                 others


      Key Pipeline Chronic Heart                Omecamtiv Mecarbil, KERENDIA (finerenone), Tirzepatide (LY3298176), CardiAMP Cell Therapy, Ziltivekimab (NN6018),
       Failure Therapies                         REVASCOR (rexlemestrocel-L), Levosimendan (TNX-103), Semaglutide, Balcinrenone (AZD9977) + dapagliflozin, Mitiperstat
                                                 (AZD4831), Vicadrostat (BI 690517) + Empagliflozin, Cimlanod (CXL-1427/BMS-986231), Lenrispodun (ITI - 214), CRD-
                                                 740, HU6, and others

Scope of the Chronic Heart Failure Market Report

    --  Therapeutic Assessment: Chronic Heart Failure current marketed and
        emerging therapies
    --  Chronic Heart Failure Market Dynamics: Key Market Forecast Assumptions
        of Emerging Chronic Heart Failure Drugs and Market Outlook
    --  Competitive Intelligence Analysis: SWOT analysis and Market entry
        strategies
    --  Unmet Needs, KOL's views, Analyst's views, Chronic Heart Failure Market
        Access and Reimbursement

Download the report to understand which factors are driving chronic heart failure market trends @ Chronic Heart Failure Market Trends

Table of Contents



     1         
     Key Insights



     2         
     Report Introduction



     3         
     Executive Summary of CHF



     4         
     CHF Market Overview at a Glance



     4.1       
     Market Share Distribution (%) of CHF in 2020: By Therapies



     4.2       
     Market Share Distribution (%) of CHF in 2034: By Therapies



     5         
     Key Events



     6         
     Epidemiology and Market Forecast Methodology



     7         
     Disease Background and Overview



     7.1       
     Introduction



     7.2       
     Causes of CHF



     7.3       
     Signs and Symptoms



     7.4       
     Stages of Heart Failure



     7.5       
     Classification of Heart Failure



     7.6       
     Common Pathophysiologic Mechanisms in Heart Failure



     7.7       
     Biomarkers for the Heart Failure



     7.8       
     Diagnosis


      7.8.1     
     Differential Diagnosis



     8         
     Treatment



     8.1       
     Guidelines


      8.1.1       Guideline for the Management of Heart Failure: American College of Cardiology/American Heart Association Joint Committee on
                   Clinical Practice Guidelines (2022)


      8.1.2     
     European Society of Cardiology (ESC) Guidelines for the Diagnosis and Treatment of Acute and CHF (Updated, 2023)


      8.1.3       American College of Cardiology (ACC), American Heart Association (AHA), and Heart Failure Society of America (HFSA) (2021)


      8.1.4     
     CHF in Adults: Diagnosis and Management (National Institute for Health and Care Excellence [NICE] Guidelines 2018)


      8.1.5     
     NICE Acute Heart Failure: Diagnosis and Management (Updated; 2021)



     9         
     Epidemiology and Patient Population



     9.1       
     Key Findings



     9.2       
     Assumptions and Rationale



     9.3       
     Total Diagnosed Prevalent Cases of Heart Failure in the 7MM



     9.4       
     United States


      9.4.1     
     Total Diagnosed Prevalent Cases of Heart Failure in the United States


      9.4.2     
     Gender-specific Cases of Heart Failure in the United States


      9.4.3     
     Ejection Fraction-specific Cases of Heart Failure in the United States


      9.4.4     
     NYHA Class-specific Cases of Heart Failure in the United States


      9.4.5     
     Type-specific Cases of Heart Failure in the United States


      9.4.6     
     Age-specific Cases of Heart Failure in the United States



     9.5       
     EU4 and the UK


      9.5.1     
     Total Diagnosed Prevalent Cases of Heart Failure in EU4 and the UK


      9.5.2     
     Gender-specific Cases of Heart Failure in EU4 and the UK


      9.5.3     
     Ejection Fraction-specific Cases of Heart Failure in EU4 and the UK


      9.5.4     
     NYHA Class-specific Cases of Heart Failure in EU4 and the UK


      9.5.5     
     Type-specific Cases of Heart Failure in EU4 and the UK


      9.5.6     
     Age-specific Cases of Heart Failure in EU4 and the UK



     9.6       
     Japan


      9.6.1     
     Total Diagnosed Prevalent Cases of Heart Failure in Japan


      9.6.2     
     Gender-specific Cases of Heart Failure in Japan


      9.6.3     
     Ejection Fraction-specific Cases of Heart Failure in Japan


      9.6.4     
     NYHA Class-specific Cases of Heart Failure in Japan


      9.6.5     
     Type-specific Cases of Heart Failure in Japan


      9.6.6     
     Age-specific Cases of Heart Failure in Japan



     10        
     Patient Journey



     11        
     Marketed Drugs



     11.1      
     Key Competitor



     11.2      
     ENTRESTO (sacubitril and valsartan): Novartis and Otsuka Pharmaceutical


      11.2.1    
     Product Description


      11.2.2    
     Regulatory Milestones


      11.2.3    
     Other Developmental Activities


      11.2.4    
     Safety and Efficacy



     11.3      
     JARDIANCE (empagliflozin): Boehringer Ingelheim/Eli Lilly


      11.3.1    
     Product Description


      11.3.2    
     Regulatory Milestones


      11.3.3    
     Other Development Activities


      11.3.4    
     Safety and Efficacy



     11.4      
     VERQUVO (vericiguat): Bayer and Merck


      11.4.1    
     Product Description


      11.4.2    
     Regulatory Milestones


      11.4.3    
     Other Development Activities


      11.4.4    
     Clinical Development


      11.4.4.1  
     Clinical Trial Information


      11.4.5    
     Safety and Efficacy



     11.5      
     FARXIGA/FORXIGA (dapagliflozin): AstraZeneca


      11.5.1    
     Product Description


      11.5.2    
     Regulatory Milestones


      11.5.3    
     Other Development Activities


      11.5.4    
     Safety and Efficacy



     11.6      
     CORLANOR/CORALAN/PROCORALAN (Ivabradine): Amgen and Servier


      11.6.1    
     Product Description


      11.6.2    
     Regulatory Milestones


      11.6.3    
     Other Development Activities


      11.6.4    
     Safety and Efficacy



     11.7      
     SAMTASU/SAMSCA (Tolvaptan Sodium Phosphate): Otsuka Pharmaceutical


      11.7.1    
     Product Description


      11.7.2    
     Regulatory Milestone


      11.7.3    
     Safety and Efficacy



     11.8      
     FUROSCIX (furosemide Injection): scPharmaceuticals


      11.8.1    
     Product Description


      11.8.2    
     Regulatory Milestone


      11.8.3    
     Other Development Activity


      11.8.4    
     Safety and Efficacy



     11.9      
     INJECTAFER (ferric carboxymaltose): American Regent, Vifor Pharma, and Daiichi Sankyo


      11.9.1    
     Product Description


      11.9.2    
     Regulatory Milestones


      11.9.3    
     Other Development Activities


      11.9.4    
     Safety and Efficacy



     11.1      
     INPEFA (sotagliflozin): Lexicon Pharmaceuticals and Viatris


      11.10.1   
     Product Description


      11.10.2   
     Regulatory Milestones


      11.10.3   
     Other Development Activities


      11.10.4   
     Safety and Efficacy



     12        
     Emerging Drugs



     12.1      
     Key Cross Competition



     12.2      
     Omecamtiv Mecarbil: Cytokinetics


      12.2.1    
     Product Description


      12.2.2    
     Other Developmental Activities


      12.2.3    
     Clinical Development


      12.2.3.1  
     Clinical Trial Information in CHF


      1.1.3     
     Safety and Efficacy



     12.3      
     KERENDIA (finerenone): Bayer


      12.3.1    
     Product Description


      12.3.2    
     Other Developmental Activities


      12.3.3    
     Clinical Development


      12.3.3.1  
     Clinical Trial Information in CHF


      12.3.4    
     Safety and Efficacy



     12.4      
     Tirzepatide (LY3298176): Eli Lilly and Company


      12.4.1    
     Product Description


      12.4.2    
     Other Developmental Activities


      12.4.3    
     Clinical Development


      12.4.3.1  
     Clinical Trial Information in CHF


      12.4.4    
     Safety and Efficacy



     12.5      
     CardiAMP Cell Therapy: BioCardia


      12.5.1    
     Product Description


      12.5.2    
     Other Developmental Activities


      12.5.3    
     Clinical Development


      12.5.3.1  
     Clinical Trial Information in CHF


      12.5.4    
     Safety and Efficacy



     12.6      
     Ziltivekimab (NN6018): Novo Nordisk


      12.6.1    
     Product Description


      12.6.2    
     Other Developmental Activities


      12.6.3    
     Clinical Development


      12.6.3.1  
     Clinical Trial Information in CHF



     12.7      
     REVASCOR (rexlemestrocel-L): Mesoblast


      12.7.1    
     Product Description


      12.7.2    
     Other Developmental Activities


      12.7.3    
     Clinical Development


      12.7.3.1  
     Clinical Trial Information in CHF


      12.7.4    
     Safety and Efficacy



     12.8      
     Levosimendan (TNX-103): Tenax Therapeutics


      12.8.1    
     Product Description


      12.8.2    
     Other Developmental Activities


      12.8.3    
     Clinical Development


      12.8.3.1  
     Clinical Trial Information in CHF


      12.8.4    
     Safety and Efficacy



     12.9      
     Semaglutide: Novo Nordisk


      12.9.1    
     Product Description


      12.9.2    
     Other Developmental Activities


      12.9.3    
     Clinical Development


      12.9.3.1  
     Clinical Trial Information in CHF


      12.9.4    
     Safety and Efficacy



     12.1      
     Balcinrenone (AZD9977) + dapagliflozin: AstraZeneca


      12.10.1   
     Product Description


      12.10.2   
     Other Developmental Activities


      12.10.3   
     Clinical Development


      12.10.3.1 
     Clinical Trial Information in CHF


      12.10.4   
     Safety and Efficacy



     12.11     
     Mitiperstat (AZD4831): AstraZeneca


      12.11.1   
     Product Description


      12.11.2   
     Clinical Development


      12.11.2.1 
     Clinical Trial Information in CHF


      12.11.3   
     Safety and Efficacy



     12.12     
     Vicadrostat (BI 690517) + Empagliflozin: Boehringer Ingelheim


      12.12.1   
     Product Description


      12.12.2   
     Clinical Development


      12.12.2.1 
     Clinical Trial Information in CHF



     12.13     
     Cimlanod (CXL-1427/BMS-986231): Bristol Myers Squibb


      12.13.1   
     Product Description


      12.13.2   
     Clinical Development


      12.13.2.1 
     Clinical Trial Information in CHF


      12.13.3   
     Safety and Efficacy



     12.14     
     Lenrispodun (ITI - 214): Intra-Cellular Therapies


      12.14.1   
     Product Description


      12.14.2   
     Clinical Development


      12.14.2.1 
     Clinical Trial Information in CHF


      12.14.3   
     Safety and Efficacy



     12.15     
     CRD-740: Cardurion Pharmaceuticals


      12.15.1   
     Product Description


      12.15.2   
     Other Developmental Activities


      12.15.3   
     Clinical Development


      12.15.3.1 
     Clinical Trial Information in CHF


      12.15.4   
     Safety and Efficacy



     12.16     
     HU6: Rivus Pharmaceuticals


      12.16.1   
     Product Description


      12.16.2   
     Other Developmental Activities


      12.16.3   
     Clinical Development


      12.16.3.1 
     Clinical Trial Information in CHF


      12.16.4   
     Safety and Efficacy



     13        
     CHF: 7MM Analysis



     13.1      
     Key Findings



     13.2      
     Market Outlook



     13.3      
     Conjoint Analysis



     13.4      
     Key Market Forecast Assumptions


      13.4.1    
     Cost Assumptions and Rebates


      13.4.2    
     Pricing Trends


      13.4.3    
     Analogue Assessment


      13.4.4    
     Launch Year and Therapy Uptakes



     13.5      
     Total Market Size of CHF in the 7MM



     13.6      
     United States Market Size


      13.6.1    
     Total Market Size of CHF in the United States


      13.6.2    
     Market Size of CHF by Therapies in United States



     13.7      
     EU4 and the UK Market Size


      13.7.1    
     Total Market Size of CHF in EU4 and the UK


      13.7.2    
     Market Size of CHF by Therapies in EU4 and the UK



     13.8      
     Japan Market Size


      13.8.1    
     Total Market Size of CHF in Japan


      13.8.2    
     Market Size of CHF by Therapies in Japan



     14        
     Unmet needs



     15        
     SWOT Analysis



     16        
     KOL Views



     17        
     Market Access and Reimbursement



     17.1      
     United States


      17.1.1    
     Centre for Medicare and Medicaid Services (CMS)



     17.2      
     EU4 and the UK


      17.2.1    
     Germany


      17.2.2    
     France



     12.6      
     Ziltivekimab (NN6018): Novo Nordisk


      12.6.1    
     Product Description


      12.6.2    
     Other Developmental Activities


      12.6.3    
     Safety and Efficacy


      17.2.3    
     Italy


      17.2.4    
     Spain


      17.2.5    
     United Kingdom



     17.3      
     Japan


      17.3.1    
     MHLW



     17.4      
     CHF Market Access and Reimbursement



     18        
     Appendix



     18.1      
     Bibliography



     18.2      
     Report Methodology



     19        
     DelveInsight Capabilities



     20        
     Disclaimer



     21        
     About DelveInsight

Related Reports

Chronic Heart Failure Epidemiology Forecast

Chronic Heart Failure Epidemiology Forecast - 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the chronic heart failure epidemiology trends.

Chronic Heart Failure Pipeline

Chronic Heart Failure Pipeline Insight - 2024 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key CHF companies, including Zensun (Shanghai) Sci & Tech, Cytokinetics, Mesoblast, Shanghai Hongyitang Biopharmaceutical Technology, Tasly Pharmaceuticals, Ionis Pharmaceuticals, Berlin Cures, CardioCell, Help Therapeutics, Eli Lilly and Company, Chong Kun Dang Pharmaceutical, Antlia Biosciences, Cardiol Therapeutics, among others.

Acute Coronary Syndrome Market

Acute Coronary Syndrome Market Insights, Epidemiology, and Market Forecast - 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key ACS companies, including Novartis, Boehringer Idorsia Pharmaceuticals, Viatris, Recardio, AstraZeneca, Faraday Pharmaceuticals, DalCor Pharmaceuticals, Roche, Jiangsu Vcare PharmaTech, CeleCor Therapeutics, Novo Nordisk, Bristol Myers Squibb, Johnson & Johnson Innovative Medicine, CellProthera, BioCardia, Kancera, Amgen, Arrowhead Pharmaceuticals, Abcentra, among others.

Acute Coronary Syndrome Pipeline

Acute Coronary Syndrome Pipeline Insight - 2024 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key acute coronary syndrome companies, including Janssen Research & Development, LLC, DalCor Pharmaceuticals, Hyloris Pharmaceuticals, among others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Contact Us

Shruti Thakur
info@delveinsight.com
+14699457679
www.delveinsight.com

Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg

View original content:https://www.prnewswire.com/news-releases/chronic-heart-failure-market-to-observe-stunning-growth-at-a-cagr-of-10-by-2034-owing-to-strong-uptake-of-entresto-and-approved-sglt2-inhibitors-along-with-emergence-of-new-class-of-therapies--delveinsight-302357036.html

SOURCE DelveInsight Business Research, LLP